Close Menu

NEW YORK – Sherlock Biosciences on Friday said that it has licensed exclusive US rights to CRISPR-Cas12 diagnostic technology from Shanghai-based Tolo Biotech.

In return, Sherlock has granted Tolo exclusive rights to the CRISPR-Cas13 SHERLOCK diagnostic platform in Greater China. Financial details of the agreement have not been disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.